Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 3
2016 1
2018 1
2019 1
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, Kreuzer J, Cronin L, Cotton D, Grauer C, Brueckmann M, Chernyatina M, Donnan G, Ferro JM, Grond M, Kallmünzer B, Krupinski J, Lee BC, Lemmens R, Masjuan J, Odinak M, Saver JL, Schellinger PD, Toni D, Toyoda K; RE-SPECT ESUS Steering Committee and Investigators. Diener HC, et al. N Engl J Med. 2019 May 16;380(20):1906-1917. doi: 10.1056/NEJMoa1813959. N Engl J Med. 2019. PMID: 31091372 Clinical Trial.
Heavy Metals and Essential Metals Are Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease.
Babić Leko M, Mihelčić M, Jurasović J, Nikolac Perković M, Španić E, Sekovanić A, Orct T, Zubčić K, Langer Horvat L, Pleić N, Kiđemet-Piskač S, Vogrinc Ž, Pivac N, Diana A, Borovečki F, Hof PR, Šimić G. Babić Leko M, et al. Among authors: kidemet piskac s. Int J Mol Sci. 2022 Dec 27;24(1):467. doi: 10.3390/ijms24010467. Int J Mol Sci. 2022. PMID: 36613911 Free PMC article.
Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society.
Habek M, Adamec I, Barun B, Bašić Kes V, Bogoje Raspopović A, Duka Glavor K, Gabelić T, Grzinčić T, Jukić M, Jurašić MJ, Kiđemet-Piskač S, Komšo M, Rimac J, Lazibat I, Lukić B, Marčinko A, Matijaca M, Ratković M, Šapina L, Vuletić V, Mirošević Zubonja T, Krbot Skorić M. Habek M, et al. Among authors: kidemet piskac s. Croat Med J. 2022 Aug 31;63(4):379-388. doi: 10.3325/cmj.2022.63.379. Croat Med J. 2022. PMID: 36046935 Free PMC article. Review.
The Association of Essential Metals with APOE Genotype in Alzheimer's Disease.
Babić Leko M, Jurasović J, Nikolac Perković M, Španić E, Sekovanić A, Orct T, Lukinović Škudar V, Bačić Baronica K, Kiđemet-Piskač S, Vogrinc Ž, Pivac N, Borovečki F, Hof PR, Šimić G. Babić Leko M, et al. Among authors: kidemet piskac s. J Alzheimers Dis. 2021;82(2):661-672. doi: 10.3233/JAD-210158. J Alzheimers Dis. 2021. PMID: 34057084
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia.
Kiđemet-Piskač S, Babić Leko M, Blažeković A, Langer Horvat L, Klepac N, Sonicki Z, Kolenc D, Hof PR, Boban M, Mimica N, Borovečki F, Šimić G. Kiđemet-Piskač S, et al. CNS Neurosci Ther. 2018 Aug;24(8):734-740. doi: 10.1111/cns.12814. Epub 2018 Feb 17. CNS Neurosci Ther. 2018. PMID: 29453935 Free PMC article.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.